Cassava Sciences Inc
SAVA2.290USD
+0.170+8.02%
收盘 08/04, 16:00（美东）报价延迟15分钟
110.63M总市值
亏损市盈率 TTM
关于 Cassava Sciences Inc 公司
Cassava Sciences, Inc. 是一家专注于神经科学的临床阶段生物制药公司。该公司的科学基础是稳定而非去除阿尔茨海默氏症患者大脑中的关键蛋白质。其治疗阿尔茨海默氏症的科学方法旨在同时抑制神经退行性病变和神经炎症。该公司正在开发两种生物制药资产：Simufilam 和 SavaDx。Simufilam 是其主要治疗候选产品，是一种用于治疗阿尔茨海默氏症痴呆症的口服药物。Simufilam 针对的是阿尔茨海默氏症患者大脑中一种名为细丝蛋白 A (FLNA) 的蛋白质的变异形式。该公司正在对阿尔茨海默氏症痴呆症患者进行两项随机安慰剂对照的口服 simufilam III 期临床试验。SavaDx 是其主要研究诊断候选产品，是一种通过少量血液样本检测阿尔茨海默氏症存在的方法。 SavaDx 是一种仅供研究使用、与安全无关的探索性生物标志物。
公司简介
公司代码SAVA
公司名称Cassava Sciences Inc
上市日期Jul 14, 2000
CEOMr. Richard J. (Rick) Barry
员工数量30
证券类型Ordinary Share
年结日Jul 14
公司地址6801 N. Capital of Texas Highway
城市AUSTIN
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编78731
电话15125012444
网址https://www.cassavasciences.com/
公司代码SAVA
上市日期Jul 14, 2000
CEOMr. Richard J. (Rick) Barry
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
469.56K
+33.33%
Mr. Eric J. Schoen
Mr. Eric J. Schoen
Chief Financial Officer
Chief Financial Officer
11.50K
-35.61%
Dr. Robert Z. Gussin, Ph.D.
Dr. Robert Z. Gussin, Ph.D.
Independent Director
Independent Director
10.62K
-16.66%
Mr. Michael J. O'Donnell, Esq.
Mr. Michael J. O'Donnell, Esq.
Independent Director
Independent Director
6.87K
-16.66%
Dr. Jack Moore, Ph.D.
Dr. Jack Moore, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Patrick J. Scannon, M.D., Ph.D.
Dr. Patrick J. Scannon, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Freda Nassif
Ms. Freda Nassif
Chief Business Officer
Chief Business Officer
--
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Robert Anderson, Jr.
Mr. Robert Anderson, Jr.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
469.56K
+33.33%
Mr. Eric J. Schoen
Mr. Eric J. Schoen
Chief Financial Officer
Chief Financial Officer
11.50K
-35.61%
Dr. Robert Z. Gussin, Ph.D.
Dr. Robert Z. Gussin, Ph.D.
Independent Director
Independent Director
10.62K
-16.66%
Mr. Michael J. O'Donnell, Esq.
Mr. Michael J. O'Donnell, Esq.
Independent Director
Independent Director
6.87K
-16.66%
Dr. Jack Moore, Ph.D.
Dr. Jack Moore, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Patrick J. Scannon, M.D., Ph.D.
Dr. Patrick J. Scannon, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.78%
Nachtrab (Matthew)
4.69%
The Vanguard Group, Inc.
4.49%
Barbier (Remi)
4.28%
Two Sigma Investments, LP
2.81%
Other
76.95%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.78%
Nachtrab (Matthew)
4.69%
The Vanguard Group, Inc.
4.49%
Barbier (Remi)
4.28%
Two Sigma Investments, LP
2.81%
Other
76.95%
股东类型
持股股东
占比
Investment Advisor
16.43%
Individual Investor
12.79%
Investment Advisor/Hedge Fund
5.95%
Research Firm
4.58%
Hedge Fund
4.46%
Bank and Trust
0.58%
Pension Fund
0.30%
Venture Capital
0.11%
Other
54.80%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
353
21.84M
45.21%
-1.76M
2025Q1
363
22.22M
46.00%
-1.56M
2024Q4
360
23.73M
49.12%
+4.41M
2024Q3
371
20.81M
43.35%
+1.72M
2024Q2
372
16.74M
35.19%
-1.63M
2024Q1
372
14.95M
34.46%
-4.56M
2023Q4
382
18.11M
42.87%
+1.40M
2023Q3
392
15.72M
37.42%
-103.08K
2023Q2
410
14.43M
34.53%
-1.76M
2023Q1
415
14.61M
34.97%
-1.98M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
3.27M
6.78%
-132.04K
-3.88%
Mar 31, 2025
Nachtrab (Matthew)
2.27M
4.69%
+2.27M
--
Aug 16, 2024
The Vanguard Group, Inc.
2.44M
5.06%
-60.35K
-2.41%
Mar 31, 2025
Barbier (Remi)
2.07M
4.28%
+727.36K
+54.36%
Sep 30, 2024
Two Sigma Investments, LP
1.36M
2.81%
+190.09K
+16.26%
Mar 31, 2025
Robertson (Sanford R)
1.34M
2.78%
-5.00K
-0.37%
May 16, 2024
Geode Capital Management, L.L.C.
1.03M
2.13%
+19.60K
+1.95%
Mar 31, 2025
State Street Global Advisors (US)
873.95K
1.81%
-122.72K
-12.31%
Mar 31, 2025
J.P. Morgan Securities LLC
749.56K
1.55%
+384.11K
+105.10%
Mar 31, 2025
Susquehanna International Group, LLP
552.02K
1.14%
+271.63K
+96.87%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
0.2%
Texas Capital Texas Small Cap Equity Index ETF
0.09%
iShares Micro-Cap ETF
0.02%
ProShares Hedge Replication ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
ALPS Medical Breakthroughs ETF
0%
iShares Morningstar Small-Cap ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
Texas Capital Texas Equity Index ETF
0%
查看更多
iShares Neuroscience and Healthcare ETF
占比0.2%
Texas Capital Texas Small Cap Equity Index ETF
占比0.09%
iShares Micro-Cap ETF
占比0.02%
ProShares Hedge Replication ETF
占比0%
iShares ESG Aware MSCI USA Small-Cap ETF
占比0%
ALPS Medical Breakthroughs ETF
占比0%
iShares Morningstar Small-Cap ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0%
Texas Capital Texas Equity Index ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
